A new study reports for the first time that injection of neuropeptide vasoactive intestinal peptide (VIP) directly into the eye of mice enhanced corneal graft survival. A new study in the American ...
Kudo, T., Tahara, Y., Gamble, K.L., McMahon, D.G., Block, G.D., and Colwell, C.S. (2013). Vasoactive intestinal peptide produces long-lasting changes in neural ...
The study of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) has expanded markedly over recent decades, establishing these neuropeptides as pivotal ...
Therapy with immune checkpoint inhibitors has become a new therapeutic option for several types of cancer, but immune-related adverse events can limit their use. 1 Outside of clinical studies, ...
The neuropeptide vasoactive intestinal peptide (VIP) has been shown to inhibit macrophage proinflammatory actions, promote a positive Th2/Th1 balance, and stimulate regulatory T-cell production. The ...
Use of vasoactive intestinal peptide (VIP) to treat critical COVID-19 respiratory failure in patients with comorbidities has shown promise. Researchers presented findings from a prospective, ...
GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief "), a biopharmaceutical company seeking to provide patients therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback